Abstract
This chapter presents the clinical use of OKT3. It discusses the role of cytokine release and xenosensitization. The clinical use of immunosuppressive anti-T cell murine monoclonal antibodies (MoAbs) has so far mostly been confined to transplantation programs. The chapter presents an indicative although non-exhaustive list of the different membrane molecules targeted by MoAbs used as immunosuppressors in transplantation. The MoAb that has been the most widely used in this setting is OKT3 (anti-CD3). OKT3 has been shown by different authors to be a very potent immunosuppressor able effectively to treat and also prevent acute allograft rejection. OKT3, thus, is a good example of a MoAb that in many transplantation centers is progressively replacing conventional serotherapy with polyclonal anti-lymphocyte sera. It has been a common experience of all centers using OKT3 that the first injections of MoAb invariably induce a flu-like syndrome, including in variable proportions depending on the patient, chills, headache, pyrexia, vomiting, diarrhea, tachycardia, respiratory distress, hypotension, and arthragia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
